WO2015151115A1

WO2015151115A1 - Liquid pharmaceutical composition of adalimumab

Info

Publication number: WO2015151115A1
Application number: PCT/IN2015/000092
Authority: WO
Inventors: Himanshu Gadgil; Chandresh CHHATBAR; Vijaykant PANDEY
Original assignee: Intas Pharmaceuticals Limited
Priority date: 2014-04-02
Filing date: 2015-02-18
Publication date: 2015-10-08
Also published as: US20200405864A1; IN2014MU01248A; EP3125928A4; US10688187B2; US20170106090A1; CA2944330A1; EP3125928A1

Abstract

The present invention relates to a liquid pharmaceutical composition comprising an anti-TNFα antibody, buffer, stabilizer, and surfactant.

Description

LIQUID PHARMACEUTICAL COMPOSITION OF ADALIMUMAB

RELATED APPLICATIONS

This appl ication is related to Indian Provisional Application 1 248/ UM/2014 filed 02^nd Apr, 2014 and is incorporated herein in its entirety.

FIELD OF THE INVENTION

The present invention relates to a l iquid pharmaceutical composition comprising an

anti-TNFct antibody, buffer, sugar, and surfactant.

BACKG ROUND OF THE INVENTION

Tumor necrosis factor is a polypeptide cytokine involved in inflammation and the acute phase response. TNF-alpha is present in larger quantities in persons with rheumatoid arthritis or Crohn's disease. It is also involved i Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PA), Ankylosing Spondyl itis (AS), Ulcerative Col itis and Plaque Psoriasis. Direct inhibition of TNF-alpha by the biological agents has produced signi ficant advances in rheumatoid arthritis and other auto-immune disease treatment and has validated the extra-cell ular inhibition of this pro-inflammatory cytokine as an effective therapy. One such biological agent is Adalimumab.

Adalimumab (Anti-TNFa antibody), marketed as HUMIRA® by Abott Inc., is a recombinant human IgG l monoclonal anti body speci fic for human tumor necrosis factor (TN F). Adal i mumab, was created usi ng phage display technology resulting in an anti body with human deri ved heavy and l ight chai n variable regions and human IgG l constant regions. Adalimumab is prod uced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific Viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. "

General ly, proteins have a very short half-li fe, and undergo clenaturation (such as aggregation, dissociation, and adsorption on the surface of vessels) upon exposure to various factors such as unfavorable temperatures, water-air interface, high-pressure, physical/ mechanical stress, organic solvents and microbial contamination. Consequently, the denatured protein loses intrinsic physicochemical properties and physiological activity. Denaturation of proteins is often irreversible, and therefore proteins, once denatured, may not recover their native properties to the initial state.

In the biopharmaceutical industry, the long term storage o f protei ns, prepared usin recombi nant DNA techno log is generally a difficult task. To overcome the stability problem of proteins in aqueous formulations, therapeutic protein products are made more stable via lyophilization (freeze-drying). Lyophilized products are usually accompanied by sterile aqueous media for reconstitution. After reconstitution, the formulations typically have short useful storage lives, even when stored at low temperatures (e.g., 5°C). Example of TNF alpha inhibitors which are available in the market in the lyophilized form are Enbrel® and Remicade® and both the compositions should be reconstituted before use.

Typical practices to improve polypeptide stability can be addressed by varying the concentration of elements with the formulation, or by adding excipients to modify the formulation.

US5580856 discloses the stabilization of dried proteins against loss of biological activity in the formulations by adding a reconstitution stabi l izer upon rehydration of the dried protein. A kit for producing a formulation by dissolving the dried composition i n a solvent contain i ng the reconstitution stabil izer is also described.

L S61 7 1586 discloses a stable _: aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol, along with uses for such a formulation.

EP 1314437 relates to an invention of stabilized preparations containing an antibody in a glycine buffer and/ or a histidine buffer and also provides processes for preparing a protein-containing stabilized preparation, comprising adj usting the pH with a basic amino acid or a basic amino acid derivative or a salt thereof.

EP 1478394 discloses about the invention that relates to an aqueous pharmaceutical composi tion suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobul in, methods of manufacture, methods of administration and kits containing same.

US8216583 disclose formulation of human antibodies for treating TNF-a associated disorder. The antibody claimed in the invention is adal imumab. It discloses a l iquid aqueous pharmaceutical formu lation is descri bed which has a h igh protei n concentration, a pH of between about 4 and about 8, and enhanced stability.

: US8420081 discloses an aqueous formulation comprising water and a protein, and methods of making the same. The invention is directed towards the findings that proteins formulated in water maintain sol ubi l ity, as well as stability, even at high concentrations, during long-term l iquid storage or other processi ng steps, such as freeze/thawi ng and lyoph i l i zation. Hence, there is a need for a stable aqueous pharmaceutical formulation with an extended shel f life, comprising an antibody which is suitable for therapeutic use to inh ibit or counteract detrimental TNFa activity. There is also a need for a stable aqueous pharmaceutical formulation with an extended shelf life, comprising an antibody suitable for therapeutic use which is easily administered and contains a high protein concentration. ·

OBJECT OF TH E INVENTION

The main object of the present invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody along with pharmaceutically acceptable carriers.

Another object of the present invention is to provide a novel and stable pharmaceutical composition comprisi ng adal imumab (anti-TNFa antibody), bu ffer, stabi l izer, surfactant and pH range of 4.5 to 6.5.

Yet another object of the present invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody comprising a buffer system selected from the group consisting of glycine, acetate, arginine, succinate, histidine either alone or a combination thereof.

Yet another object of the pre'sent invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody comprising sugar or po lyol stabilizer selected from the group consisting of monosaccharide such as glucose and mannose, and the like either^' alone or in combination thereof, dissacharides such as sucrose, trehalose, and maltose, and the like either alone or in combination thereof, sugar, alcohols: such as mannitol and xyl itol, and the like either alone or in combination thereof.

Yet another object of the present invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody comprising the ionic surfactant selected from the group consisting of a polysorbate-based non-ionic surfactant and a poloxamer-based non-ionic surfactant or a combination thereof.

Yet another object of the present i nvention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody wherein the formulation is mai ntained at a pH o f about 4.5 to 6.5 , more preferably at pH 5.0 to 6.0, in a buffer system selected from the group consisting of glycine, acetate, arginine, succinate, histidine either alone or a combination thereof. Yet another object of the present invention is to provide a novel and stable pharmaceutical composition which encompasses adalimumab as anti-TNFa antibody comprising glycine, acetate and arginine as buffer either alone or in combination thereof, sucrose as stabilizer, polysorbate 80 as surfactant and. formulation is maintained at pH of about 5.0 to 6.0.

Yet another object of the present invention is to provide a novel and stable pharmaceutical composition comprising adalimumab as anti-TNFa antibody, buffer, stabilizer and surfactant; wherein buffer is at concentration of 5 mM to 25 mM and wherein the pH of the composition is in a range of about 4.5 to 6.5; wherein stabilizer is at concentration of 0.1 % to 20% w/v; wherein surfactant is at concentration of 0.004% to 0.4% w/v.

SUMMARY OF THE INVENTION

The main aspect of the present invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody along with pharmaceutically acceptable carriers.

A nother aspect of the present invention is to provide a novel and stable pharmaceutical compositi on comprising adal imumab (of anti-TN Fa anti body), buffer, stabi l izer, surfactant and pH range o f 4.5 to 6.5.

Yet another aspect of the present invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody comprising a buffer system selected from the group consisting of glycine, acetate, arginine, succinate, histicline either alone or a combination thereo f.

Yet another aspect of the present invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody comprising sugar or polyol stabilizer selected from the group consisting of monosaccharide such as glucose and mannose, and the like either alone or in combination thereof, dissacharides such as sucrose, trehalose, and maltose, and the like either alone or in combination thereof, sugar alcohols such as mannitol and xyl itol, and the l ike either alone or in combination thereof.

Yet another aspect of the present invention is to provide a novel and stable pharmaceutical composition of anti-TNFa antibody comprising the ionic surfactant selected from the group consisting of a polysorbate-based non-ionic surfactant and a poloxamer-based non-ionic surfactant or a combination thereof. Yet anotiier aspect of the present i nvention is to provide a novel and stable pharmaceutical composition of anti-TN Fa antibody wherein the formulation is maintai ned at a pH of about 4.5 to 6.5 , more preferably at pH 5.0 to 6.0, in a buffer system selected from the group consisting of glycine, acetate, arginine, succinate, histidine, arginine either alone or a combination thereof.

Yet another aspect of the present invention is to provide a novel and stable pharmaceutical composition which encompasses adal imumab as anti-TNFa antibody comprising glycine, acetate and argin ine as buffer either alone or in combination thereof, sucrose as stabil izer, polysorbate 80 as surfactant and formulation is maintai ned at pH of about 5.0 to 6.0.

Yet another aspect of the present invention is to provide a novel and stable pharmaceutical composition comprising adalimumab as anti-TNFa antibody, buffer, stabilizer and surfactant; wherein buffer is at concentration of 5 mM to 25 mM and wherein the pH of the composition is i n a range of about 4.5 to 6.5 ; wherein stabi lizer is at concent ration o f 0. 1 % to 20% w/v; wherein sur factant is at concentration of 0.004% to 0.4% w/v.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the comparative CEX-HPLC profile of Adalimumab Formulations 1 ,2,3 & RMP at 0D, 7D

& 1 4D days.

Figu re 2 shows the comparative SEC-HPLC profi le of Adalimumab Formulations 1 ,2,3 & RMP at 0 D, 7D & 14D days.

Figure 3, Figure 4, Figure 5 & Figure 6 shows DSC profile of Formulations 1 , 2, 3 & RMP respectively.

Figu re 7 shows the stress study CEX-HPLC profile of Formulation 1 , 2 & 3 at 40°C for 0D, 7D & 1 4D days.

Figu re 8 shows the Real Time (RT) CEX-HPLC pro fi le o f Formulation 1 , 2 & 3 at 5°C for 0 day, 1 M, 2M, 3M & 6M.

Figure 9 shows the Accelerated Temperature (AT) CEX-HPLC profile of Formulation 1 , 2 & 3 at 5°C for 0 day, 1 M, 2M & 3M.

Figu re 10 shows the stress study SEC-HPLC profile of Formulation 1 , 2 & 3 at 40°C for OD, 7D & I 4D days.

Figu re 1. 1 shows the Real Time (RT) S Ec-HPLC profi le of Formulati on 1 , 2 & 3 at 5°C for 0 day, 1 M, 2M, 3M & 6M.

Figure 12 shows the Accelerated Temperature (AT) SEC-HPLC profile of Formulation 1 , 2 & 3 at 5°C for 0 day, 1M, 2M & 3M. DETAILED DESCRIPTION OF THE INVENTION

The following definitions are provided to facil itate understand ing of certain terms used throughout the specification.

The present invention relates to a liquid pharmaceutical composition comprising an anti-TNFa antibody, buffer, sugar, and surfactant.

The term "human TNFa" (which may be abbreviated as hTNFa, or simply hTNF), as used herei n, is intended to refer to a human cytokine that exists as a 1 7 kD secreted form and a 26 kD membrane associated form, the biologically active form of which is composed of a trimer of noncovalently bound 17 kD molecules. Treatment with anti-TNF monoclonal antibodies (infliximab, adalimumab and certoiizumab pegol) has been shown to provide substantial benefit to patients through reductions in both localized and systemic expression of markers associated with inflammation.

The present invention relates to a novel and stable pharmaceutical com position comprisi ng adal imumab (o f anti-TNFa antibody), buffer, stabi lizer and surfactant having H range of 4.5 to 6.5.

Adalimumab is the first phage-display-deri ved human antibody brought into the clinic, and was generated by 'guided selection' using a mouse monoclonal antibody. (Jespers L. S., Biotechnology 12, 899-903, 1994). Adal imumab (Anti-TNFa antibody), marketed as HUMIRA® by Abott Inc., is a recombinant human IgG l monoclonal antibody speci fic for human tumor necrosis factor (TNT). Adalimumab was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGl constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.

In the present i nvention, buffers are requi red for maintai ning pH o f the formulation . The bu ffer system of the present invention comprises glycine, acetate, arginine, succinate, histidine either alone or a combination thereof giving desired pFI range from 4.5 to 6.5.

In one embodiment, stabilizers used in the present invention are selected from the group that consists of: sugar or polyol stabil izer selected from the^' group consisting of monosaccharide such as gl ucose and mannose, and the like either alone or in combination thereo f, dissacharides such as sucrose, trehalose, and maltose, and the l i ke either alone or in combination thereof, sugar alcohols such as mannitol and xyl itol, and the like either alone or in combination thereof.

In the present invention, surfactant is used in order to prevent adsorption of antibody on the surface of the vial, ampoule, carpoule, cartridge or syringe. Surfactants lower surface tension of a protein solution, thereby, preventing its adsorption or aggregation on to a hydrophobic surface. Preferred surfactants of the present invention incl ude a polysorbate based non-ionic surfactant and polyoxyethylene copolymer, polyvinylpyrrolidone, either alone or in combination.

The novel aqueous pharmaceutical composition of anti-TNFcc antibody described in the present invention has the fo 1 lowing advantages :

1. Involves use of a buffer system which is selected from the group consisting of glycine, acetate, arginine either alone or a com bination thereof mai ntains the pH of^" the formulation between 4.5 to 6.5, more preferably between 5.0 to 6.0 and also mai ntains the purity o f the formulation at elevated temperature.

2. Involves use of surfactant to prevent adsorption of anti-TNFcc antibody on container.

3. Involves use of a stabilizer which provides better stability.

4. The pharmaceutical composition of present invention is maintained at pH between 5.0 to 6.0 which is critical in maintaini ng the purity and stabil ity of the aqueous composition at elevated temperatures duri ng storage.

5. Involves operational simplicity.

The specific embodiments described herein are offered by way of example only, and the invention is to-be limited by the terms of the appended claims, along with the full scope of equivalents to which such clai ms are entitled. ^'

Example 1

Screening and selection of buffer

Table 1 : Formulation com position

Method of preparation: Adalimumab formulation was prepared in fonnulation composition given in the above table by dissolving the excipients in water for injection. The protein concentration was set to 50 mg/ mL and the pH of the fonnulation is set to 5.2 similar to the reference formulation. 0.8 mL solution filled in 2 mL USP type 1 vial and sealed with coated bromobutylated rubber stopper and aluminum seal. Fil led vial were charged at 40 °C for 1 5 days stress stability study. During stabi l ity study fol lowi ng test were done:

Table 2: Pur ose of the tests

Stress stability data (14 clay at 40 °C) for selection of buffer

a) Physical appearance:

All the samples were observed to be clear and colorless till 14 Day at 40 °C for ST. b) pH:

Table 3: H of Formulation I, 2 & 3

c) CEX- HPLC:

on exchange chromatography separates analytes based on differences in the surface charge of the molecules and their concomitant varying strengths of interaction with the stationary phase. Charge-related variants expected in Molecule and their variability during storage. Propac WCX-10 column from Thermo Scientific was used on Agilent HPLC.

Tabic 4: CEX clntii of Formulation I, 2 & 3 Fi ure - 1

Observation: Based on 14 days stress data the purity of the formulation 1, 2 and 3 was comparable with the reference formulation (generic DP). Results are shown in Figure I. cl) SILC-HPLC:

Size exclusion chromatography (SEC) is size based separation of molecules. High molecular weight and low molecular weight related variants (HMWs and LMWs) can be resolved and detected using this technique. TSK G3000SWXL (7.8 mm x 300 mm) column from Tosoh Haas was used on Agilent HPLC.

Observation : Formulation ] , 2 and 3 al l shows less H VV and LM W compared to the reference formulation (Generic DP). Results are shown in Figure 2. e) Relative potency:

The biological activity of Adalimumab is determined by cell based in-vitro bio-assay. The assay is based on the neutral ization of cytotoxic effect of TNF-rx on L929 (mouse connect! ve tissue) cel l line expressing TN F receptor I (T F 1 ). Adal imumab speci fical ly neutral izes the cytotoxic activity of TNF-a in a dose dependent manner.

Observation: There is no change in potency at 40°C after 14 days as compared to initial in all Formulation.

Di fferential Scann ing Calorimetry:

DSC measures the difference in heat energy uptake between a sample solution and appropriate reference "(buffer/solvent) with increase in temperature. The transition temperatures Tm (where 50% of protein is in folded form, while 50% in unfolded) is indicator of protein stability.

Samples were analyzed on DSC (MicroCal, LLC Mlcrocalorimeter, Model No. : VP-DSC). The scan rate was set to 60 C/h and the protein concentration o f the samples loaded was 0.5 mg/m L.

Observation: The thermo gram of generic DP shows the down fall signal which is exothermic in nature and denote the aggregation of the protein at that temperature. Hence it can be said that the protein in the generic formulation matrix is susceptible to the aggregation. Formulation 1, 2 and 3 shows good thermal stability as compared to the generic formulation and Tml and Tm2 shows the higher value for all three formulation as compared to generic formulation. Based on the DSC results it can be predict that the protein (Adalimurnab) will be more stable at long term in test formulation I, 2 and 3 as compared to generic formulation. This can also be seen when correlated with the stress stability data. Results are shown in Figures 3 to 6.

Exam le 2

Stability test of Adalimurnab aqueuos thermostable formulation

Rationale: Based on the above data, all three buffer shows a good buffering capacity, and thermo stability profile. To confirm the results obtained during the initial screening, another set of stability study were carried out with the formulation 1, 2 and 3.Composition of all formulation buffer as given i below table.

Table 8: Stud condition and Time oints for Formulation 1, 2 & 3

Method of preparation : Adalimurnab formulation was prepared in formulation composition given in the above table by dissolving the excipients in water for injection. The protein concentration was set to 50 mg/ mL and the pH of the formulation is set to 5.2 similar to the reference formulation.0.8 mL solution filled in 2 mL USP type 1 vial and sealed with coated bromobutylated rubber stopper and aluminum seal. Filled vial were charged at 40 °C for 15 days stress stability study, At 5°C for 6 months and at 25°C for 6 months as described in the above table. During stability study following test were done: Table 9: Purpose of the tests

a) Physical appearance:

Samples were observed to be clear and colorless till 14D ST.6M RT & 3M AT. b) pH

STRESS DATA: at 40°C

Table 10: H (lata of Formulation I, 2 & 3

REAL T ME DATA (AT 5°C)

Table 11: H data of Formulation 1, 2 & 3

Table 12: H data of Formulation 1, 2 & 3

c) CEX data

STRESS DATA: at 40°C

Table 13: CEX data of Formulation I, 2 & 3 buffers Fi ure - 7

Observation: All the formulation are showing good stability and comparable. Results are shown, in Figure 7.

EAL TIME DATA (AT 5°C)

Table 14: CEX data of Formulation 1, 2 & 3 buffers (RT) (Figure - 8)

Observation: At 5°C after 6 month all thee formulations shows similar stability profile when analyze by CEX HPLC; there is no significant increase in the acidic or basic variant observed in all three formulation. Results are shown in Figures 8.

ACCELERATED TEMPERATURE DATA: at 25°C

Table 15: CEX data of Formulation 1, 2 & 3 buffers AT Fi ure - 9

Observation: The overall stability of all three formulations is good at 25°C after 3 month. Results are shown in Figures 9. d) SEC-HPLCdata

STRESS DATA: at40°C

Table 16: SEC data of Formulation 1, 2 & 3 buffers Fi ure - 10

Observation: All three formulations are showing good stability and comparable in SEC profile. Results are shown in Figures 10.

REAL T ME DATA (AT 5°Q

Table 18: SEC data of Formulation 1, 2 & 3 buffers (RT) (Figure - 11)

Observation: At 5°C after 6 month all thee formulations shows similar stability profile when analyze by SE HPLC; there is no significant increase in the HMW and LMW observed in all three formulation. Results are shown in Figures I I.

ACCELERATED TEMPERATURE DATA: at 25°C

Table 19: SEC data of Formulation 1, 2 & 3 buffers (AT) (Figure - 12)

Observation: At 25°C after 3 month all thee formulations shows similar stability profile when analyze by SE FiPLC; there is no significant increase in the HMW and LMW observed in all three formulation. It shows that these formulations are preventing Ada!imumab from aggregation and fragmentation. Results are shown in Figures 12. e) Potency

STRESS DATA: at 40°C

Table 20: % Potency data of Formulation 1, 2 & 3 buffers

Observation: There is no change in potency at 40°C after 14 days as compared to initial in all formul tions.

REAL TIME DATA (AT 5°Q

Table 21: % Potency data of Formulation 1, 2 & 3 bu ffers

Buffers . % Potenc

Time poin t Ϊ 0D. 1M. ,-(2M 3M

Formulation 99 99 104 1.20

Formulation 2 95 107 103

Formulation I I 114 109

Observation: There is no change in potency at after 3 Months as compared to initial in all formulations.

ACCELERATED TEMPERATURE DATA: at 25°C

Table 22: % Potency data of Formulation 1, 2 & 3 buffers

Observation: There is no change in potency at after 3 Months at 25°C as compared to initial in all formulations.

Claims

E CLAIM,

;.'l . An aqueous pharmaceutical formulation comprising an anti-TNFa antibody , buffer which is selected from the group consisting of acetate, arginine, glycine or a combination thereof, Polysorbate 80 as surfactant and Sucrose as stabil izer.

2. An aqueous pharmaceutical formulation of claim 1 , wherein an anti-TNFa antibody is Adal imumab.

3. An aqueous pharmaceutical formulation of claim 1 , wherein the concentration of Adalimumab is ; : between 1 mg/mL to 100 mg mL, preferably 50 mg/mL.

^' ;;¾.^; An aqueous pharmaceutical fonnulation of claim 1 , wherein the pH of the formulation is between pH 4.5 to 6.5, preferably at pH 5.2.

5. A n aqueous pharmaceutical form u lation of claim 1 , wherein the buffer is in the concentration of 1 mM to 100 mM, more preferably 5 mM to 20 mM.

6. An aqueous pharmaceutical formulation of claim I, wherein the Polysorbate 80 is present in the [ concentration of 0.001% to 1 %.

7. An aqueous pharmaceutical formulation of claim 1 , wherein the Sucrose is present in the concentration from 1 % to 1 0%.

8.. An aqueous pharmaceutical formulation o t Adali mumab compris ing acetate as bu ffer, suc rose and Polysorbate 80 at pH 5.2 wherein Adalimumab is present at a concentration of 1 mg/mL to 1 00 mg/mL.

9. An aqueous pharmaceutical formulation as claimed in claim 8 comprising,

a) 50 mg/mL Adalimumab

b) 1.0 mM acetate buffer

c) 9.5% sucrose

d) 0. 1 % Polysorbate 80 at pH 5.2.

1 0. An aqueous pharmaceutical formulation Adalimumab comprising arginine as buffer, sucrose and ; Polysorbate 80 at pH 5.2 wherein Adalimumab is present at a concentration of 1 mg/mL to 1 00

:^: mg/mL.

■1 1. An aqueous pharmaceutical formulation as claimed in claim 1 0 comprising,

e) 50 mg/mL Adal imu mab

f) 1 5 mM argin ine bu ffer

g) 9.5% sucrose

h) 0.1% Polysorbate 80 at pH 5.2.

¾ 2. An aqueous pharmaceutical formulation of Adalimumab comprising glycine as buffer, sucrose and Polysorbate 80 at pH 5.2 wherein Adalimumab is present at a concentration of 1 mg/mL to 100 mg/mL.

13. A n aqueous pharmaceutical formu lation as clai med i n claim 1 2 com prising,

a) 50 mg/mL Adal imumab b) 15 mM glycine buffer c) 9.5% sucrose

d) Ο. /ο Polysorbate 80 at pH 5.2